Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation
- 281 Downloads
The role of liver transplant (LT) for neuroendocrine liver metastasis (NELM) has not been completely defined. While international guidelines included LT as a potential treatment for highly selected patients with advanced NELM, recently, LT has been proposed as an alternative curative treatment for NELM for patients meeting restrictive criteria (Milan criteria).
Using a multi-institutional cohort of patients undergoing liver resection for NELM, the long-term outcomes of patients meeting Milan criteria (resected NET drained by the portal system, stable disease/response to therapies for at least 6 months, metastatic diffusion to < 50% of the total liver volume, a confirmed histology of low-grade, and ≤ 60 years) were investigated.
Among the 238 patients included in the study, 28 (12%) patients met the Milan criteria for LT with a 5-year OS of 83%. Furthermore, among patients meeting Milan criteria, subsets of patients with favorable clinic-pathological characteristics had 5-year OS rates greater than 90% including G1 patients (5-year OS, 92%), patients undergoing minor liver resection (5-year OS, 94%), patients with low number of NELM (1–2 NELM), and small tumor size (< 3 cm) (for both groups of patients, 5-year OS, 100%).
In our series, only 12% of patients met Milan criteria, and the 5-year OS after liver resection for this small selected group of patients was comparable with that reported in the literature for patients undergoing LT for NELM within Milan criteria. While LT might be the optimal treatment for patients with unresectable NELM, surgical resection should be the first option for patients with resectable NELM.
KeywordsNeuroendocrine liver metastasis Liver surgery Liver transplant
The work of Dr. Francesca Bertuzzo was supported by the Fondo Unico per la Ricerca (FUR) 2017 and the Fondazione Livia and Vittorio Tonolli, Verbania, Italy.
- Design of the work: all authors.
- Analysis and interpretation of data for the work: C. Iacono, A. Ruzzenente, and F. Bagante.
- Drafting the work: C. Iacono, A. Ruzzenente, F. Bagante.
- Revising it critically for important intellectual content: all authors.
- Final approval of the version to be published: all authors.
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: all authors.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(18):3063–72. https://doi.org/10.1200/JCO.2007.15.4377.CrossRefGoogle Scholar
- 3.Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21(9):1794–803. https://doi.org/10.1093/annonc/mdq022.CrossRefGoogle Scholar
- 6.Ruzzenente A, Bagante F, Bertuzzo F, Aldrighetti L, Ercolani G, Giuliante F et al. A Novel Nomogram to Predict the Prognosis of Patients Undergoing Liver Resection for Neuroendocrine Liver Metastasis: an Analysis of the Italian Neuroendocrine Liver Metastasis Database. J Gastrointest Surg. 2017;21(1):41–8. https://doi.org/10.1007/s11605-016-3228-6.CrossRefPubMedGoogle Scholar
- 7.Spolverato G, Bagante F, Aldrighetti L, Poultsides G, Bauer TW, Field RC et al. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. J Gastrointest Surg. 2017;21(12):2039–47. https://doi.org/10.1007/s11605-017-3491-1.CrossRefPubMedGoogle Scholar
- 18.Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. World Health Organization classification of tumours, vol 3. Lyon: International Agency for Research on Cancer; 2010.Google Scholar
- 21.R Core Development Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2015.Google Scholar
- 23.Frank E Harrell Jr with contributions from Charles Dupont and many others. Hmisc: Harrell Miscellaneous. 2016. R CRAN package available at https://cran.r-project.org/web/packages/Hmisc/index.html (last accessed on 09/12/2018)
- 24.Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63. https://doi.org/10.1200/JCO.2009.22.8510.CrossRefPubMedGoogle Scholar
- 29.Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–77. https://doi.org/10.1016/S0140-6736(15)00817-X.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev. 2009(2). https://doi.org/10.1002/14651858.CD007060.pub2.
- 33.Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130(4):677–82; discussion 82–5. https://doi.org/10.1067/msy.2001.117377.CrossRefPubMedGoogle Scholar
- 35.Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572–81. https://doi.org/10.1245/ASO.2006.03.071.CrossRefPubMedGoogle Scholar
- 36.Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87(1):47–62. https://doi.org/10.1159/000111037.CrossRefPubMedGoogle Scholar
- 37.Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103(2):172–85. https://doi.org/10.1159/000443167.CrossRefPubMedGoogle Scholar
- 39.Le Treut YP, Gregoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013;257(5):807–15. https://doi.org/10.1097/SLA.0b013e31828ee17c.CrossRefPubMedGoogle Scholar
- 40.Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76. https://doi.org/10.1159/000335597.CrossRefPubMedGoogle Scholar